Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 44 (11), 1135-64

Clinical Pharmacokinetics of Cyclophosphamide

Affiliations
Review

Clinical Pharmacokinetics of Cyclophosphamide

Milly E de Jonge et al. Clin Pharmacokinet.

Abstract

Cyclophosphamide is an extensively used anticancer and immunosuppressive agent. It is a prodrug undergoing a complicated process of metabolic activation and inactivation. Technical difficulties in the accurate determination of the cyclophosphamide metabolites have long hampered the assessment of the clinical pharmacology of this drug. As these techniques are becoming increasingly available, adequate description of the pharmacokinetics of cyclophosphamide and its metabolites has become possible. There is incomplete understanding on the role of cyclophosphamide metabolites in the efficacy and toxicity of cyclophosphamide therapy. However, relationships between toxicity (cardiotoxicity, veno-occlusive disease) and exposure to cyclophosphamide and its metabolites have been established. Variations in the balance between metabolic activation and inactivation of cyclophosphamide owing to autoinduction, dose escalation, drug-drug interactions and individual differences have been reported, suggesting possibilities for optimisation of cyclophosphamide therapy. Knowledge of the pharmacokinetics of cyclophosphamide, and possibly monitoring the pharmacokinetics of cyclophosphamide in individuals, may be useful for improving its therapeutic index.

Similar articles

See all similar articles

Cited by 66 articles

See all "Cited by" articles

References

    1. Br J Clin Pharmacol. 1979 Nov;8(5):455-8 - PubMed
    1. Drug Metab Dispos. 1997 May;25(5):544-51 - PubMed
    1. Cancer Chemother Pharmacol. 1987;20(3):219-22 - PubMed
    1. Biochem Pharmacol. 1993 Jun 22;45(12):2487-505 - PubMed
    1. Br J Clin Pharmacol. 1975 Jun;2(3):281-5 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

Feedback